A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
Principal Investigator: Dr. Erin Pettijohn
For more information on this trial, read its profile on clinicaltrials.gov here.